New research has shown that neuroendocrine tumors are more common than previously thought. Progress in our understanding of the molecular pathogenesis of these not-so-rare cancers has resulted in renewed interest in developinginnovative therapeutic options. In particular, novel molecular targeted agents have been shown to have significant anti-tumor activity, and integration of these therapies has led to critical advances in management.

In this volume, an outstanding group of the world s leaders in the field have assembled to convey their knowledge of the epidemiology, biology, and management of allthemajor types of neuroendocrine tumors. The book takes a multi-modality approach to understanding disease processes and therapeutics, including chapters on medical and surgical treatment as well as a chapter devoted to imaging. Throughout, the authors emphasize recent advances in our understanding of molecular biology and the subsequent emerging therapeutic options.

Topics include: Neoplastic Meningitis and Epidural Metastases: Evaluation and Management; Management of Brain Metastases: Surgery, Radiation, or Both?; Meningiomas/Nerve Sheath Tumors/Pituitary Tumors: Diagnosis and Treatment; Medulloblastoma/Primitive Neuroectodermal Tumor and Germ Cell Tumors: The Uncommon but Potentially Curable Primary Brain Tumors; Primary CNS Lymphoma: Overview of Current Treatment Strategies; Anaplastic Gliomas: Radiation, Chemotherapy, or Both?; Low Grade Gliomas: When and How to Treat?; Glioblastoma Multiforme: Overview of Current Treatment and Future Perspectives.

Topics in this issue?include: Targeting IGF-1R; Tyrosine Kinase Inhibitors in Lung Cancer; Targeting mTOR; Targeting Hedgehog; Mitotic Inhibitors; Topoisomerase I Inhibitors; and New Strategies and Drugs Inhibiting Folate Pathways.

This volume highlights recent developments in neuro-oncology that are not only increasing the survival rate of patients, but also improving their quality of life. Through an in-depth exploration of new therapies, including advanced diagnostic tools and a fresh perspective on molecular biology, immunology, and the clinical aspects of tumors, clinicians will gain a critical understanding of emerging therapies and techniques. Extensive coverage of tumor management and new therapeutic strategies, including gene therapy and molecularly targeted treatments are also explored, providing clinicians with new tools and tactics they can use to treat tumors of the nervous system.

Clinicians will find this handbook to be an invaluable resource for summarizing the present state of scientific and clinical knowledge in the field of neuro-oncology. In addition, practitioners in the field will uncover new tactics and therapies that will aid them in providing optimal neuro-oncological care for their patients.
* An invaluable resource that includes critical, in-depth insights into recent developments in neuro-oncology
* A fresh perspective on molecular biology, immunology, and other clinical aspects of tumors of the nervous system
* Extensive coverage of tumor management and new therapeutic strategies, including gene therapy and molecularly targeted treatments
* New tactics and therapies that will aid clinicians in their quest to provide optimal care for their neuro-oncological patients

"Advances in Cancer Research" provides invaluable information on the exciting and fast-moving field of cancer research. This thematic volume looks at "Guidance molecules in Cancer and cancer angiogenesis" and contains outstanding and original reviews.
Provides invaluable information on the exciting and fast-moving field of cancer research. This volumelooks at "Guidance molecules in Cancer and cancer angiogenesis."Outstanding and original reviews"

Topics for this issue will include: CLL: ? A Historical Perspective; Incidence & Epidemiology; Biology, Molecular Biology & Cytogenetics of CLL; What does the status of smatic hypermutations in IGVH genes tell us about the origin of CLL?; What does the status of ZAP-70 tell us about the biology of CLL?; and Approach to initial therapy: When to start therapy?

This issue of Surgical Oncology Clinics of North America, Guest Edited by Neal Wilkinson, MD, is devoted to the Management of Gastric Cancer.? Articles in this issue will focus on Epidemiology; Genetics and Prophylactic Surgery; Endoscopic Diagnosis & Staging; Gastric Stromal Tumors (GIST); Management of Early Stage Gastric Cancer; Endoscopic Mucosal Resection (EMR); Tailored Lymphadenectomy; Laparoscopic Resection Gastric Cancer - Western Experience; Gastric Cancer - Eastern Experience; Update of Gastric Cancer Clinical Trials; Preoperative and Postoperative Chemotherapy for Gastric Cancer; and Phase I and II Clinical Trials.

The existence of 'cancer stem cells' (CSCs) has been a topic of heated debate for the last few years within the field of cancer biology. Their continuous characterization in a variety of solid tumors has lead to an abundance of evidence supporting their existence. CSCs are believed to be responsible for resistance against conventional treatment regimes of chemotherapy and radiation, ultimately, leading to metastasis and patient demise. To help aid clinicians, pharmaceutical companies and academic labs investigating how to better kill these highly aggressive cells we have summarized the DNA repair mechanism(s) and their role in the maintenance and regulation of both normal and cancer stem cells. Our book represents a comprehensive investigation into the highly effective DNA repair mechanisms of CSCs and what we need to understand in order to develop more advanced therapies to eradicate them from patients. Currently, there are no other published works entirely on DNA repair and Cancer Stem Cells. In addition, our book provides a comprehensive overview of CSC isolation and characterization from a variety of solid tumor types.

This issue of the Urologic Clinics provides a timely update on Renal Cancer and the evolving treatment standards in urology.? Articles include Contemporary Imaging of the Renal Mass, Surgical Approach to Multifocal Renal Cancers, and Systemic Therapy Prior to Surgery.? Effects of the various existing surgical approaches on long-term renal function is also discussed, along with a review of the current trends in surgical management of renal cancers with specific attention to utilization of laparoscopic approach, partial nephrectomy, ablative technologies and observation.

Handbook of Clinical Neurology: Neuro-Oncology, Part II provides an overview of the most recent developments in the field of neuro-oncology, including new diagnostic imaging techniques, along with immunology, molecular biology, and clinical aspects of different types of tumors. It also considers management and new therapeutic strategies for tumors, such as gene therapy, radiation therapy, and molecularly targeted treatments. Divided into five sections encompassing 33 chapters, the book begins with a description of specific tumor types such as low-grade gliomas, anaplastic astrocytomas, and medulloblastoma and primitive neuroectodermal tumors, along with rare brain tumors like neurofibromatosis and other genetic syndromes. It then discusses tumors at special sites, from brainstem tumors to peripheral nerve tumors, tumors of the meninges, and optic, hypothalamic, and thalamic tumors. It also explains the neurological complications of systemic cancer and the adverse effects of some treatments. Clinicians and neuroscientists, as well as researchers who read this book, will gain a better understanding of the clinical features and management of the neurological manifestations of tumors.

This specialized volume of Advances in Cancer research is dedicated to the complex and largely unexplored field of intratumor diversity, with respect to differences in both genotype and phenotype among cell populations within tumors.

Dr. Talpaz has assembled top experts to write state-of-the art reviews on the management of chronic myelogenous leukemia. Some of the articles that will be of most interest include Selection of Therapy: Rational Decisions Based on Molecular Events; Is There a Potential Cure for CML in Current Therapies?; Hurdles Toward a Cure for CML: The CML Stem Cell; The CML Stem Cell in the Chronic and Advanced Disease; CML Disease Progression; Management of Ph+ ALL and CML Blast Crisis; BMT in CML in the Era of Targeted Therapy; Pharmacoeconomics: The Cost of Staying Alive; and The Significance of CML Prognostic Factors in the Era of Targeted Therapy.

This book will be a guide to understanding resistance against targeted therapeutic approaches for cancer using immunotoxins. It contains a detailed review of the history and development of targeted therapy. As well, it includes an in-depth description of the molecular and cellular mechanisms involved in cancer resistance and several novel methods to overcome resistance. Each chapter discusses different aspects of resistance and covers all the factors that may contribute to resistance in cancer cells. Finally, this volume highlights the recent findings and advances associated with tackling cancer resistance.

This volume will describe both growth-inhibitory and mucin-depleting effects of bromelain and N-acetylcysteine, on their own or in combination, in cancer. It will coherently review the pathophysiological aspects of the mucin glycoproteins in malignancies and provide an updated account of the status of bromelain and N-acetylcysteine in cancer therapy. The volume will develop the idea of using these two drugs as a combination formulation for mucin-depleting effects.

This book, written by experts from across the world, provides a comprehensive, up-to-date overview covering all aspects of posterior fossa neoplasms in pediatric patients, including medulloblastoma, ependymoma, cerebellar astrocytoma, atypical teratoid/rhabdoid tumor, chordoma, brain stem tumors, and rarer entities. For each tumor type, individual chapters are devoted to genetics, radiological evaluation using advanced imaging techniques, surgery, pathology, oncology, and radiation treatment. In addition, a separate section describes the various surgical approaches that may be adopted and offers guidance on the treatment of hydrocephalus and the role of intraoperative mapping and monitoring. Useful information is also provided on anatomy, clinical presentation, neurological evaluation, and molecular biology. The book closes by discussing in detail immediate postoperative care, the management of surgical complications, and longer-term rehabilitation and support. Posterior fossa tumors are the most common pediatric brain tumors but are often difficult to treat owing to their proximity to critical brain structures and their tendency to cause marked intracranial hypertension. Practitioners of all levels of experience will find Posterior Fossa Tumors in Children to be a richly illustrated, state of the art guide to the management of these tumors that will serve as an ideal reference in clinical practice.

This issue of Rheumatic Disease Clinics of North America provides foundational and in-depth information about paraneoplastic and cancer treatment-related rheumatic disorders, in which every practicing rheumatologist should be well-versed.? Topics covered include neoplasm risk in patients with rheumatic diseases; neoplasm risk of anti-rheumatic therapy; rheumatologic laboratory findings in malignancy; rheumatic manifestations of primary and metastatic bone tumors and paraneoplastic bone disease; neoplastic/paraneoplastic synovitis; neoplastic/paraneoplastic dermatitis, fasciitis, and panniculitis; neoplastic/paraneoplastic vasculitis, vasculopathy, and hypercoagulability; neoplastic/paraneoplastic myalgias and myositis; and less-common neoplastic/paraneoplastic syndromes.

In this issue of Surgical Oncology Clinics of North America, Guest Editor Mark Krasna and colleagues discuss a wide range of topics devoted to lung cancer.? Articles focus on pathology; updated staging systems; epidemiology of lung cancer - smoking, second hand smoke, and genetics; molecular markers for incidence, prognosis, and response to therapy; screening; diagnostic work-up; non-invasive staging techniques; surgical resection; the role of surgery following induction therapy for stage III NSCLC; the role of adjuvant chemotherapy in NSCLC (stages I-III); and much more.

Carcinoma of the lung is one of the most prevalent and aggressive types of cancer, and rates of lung cancer are on the rise.? This issue gives a comprehesive review of the most recent advances in Lung Cancer.? Epidemiology, etiology, and prevention of lung cancer is first discussed, followed by articles on pre-invasive evaluation and management, screening, pathology and molecular biology.? There is an article on the approach to the ground glass nodule.? Of great importance is the revised staging classification of Lung Cancer, which is discussed here in detail.? Articles on PET imaging, interventional pulmonary, and functional evaluation before Lung Resection are also included.? The issue then focuses on advances in treatment for early stage lung cancer, hgih risk patients with early stage lung cancer, advances in the treatment of Advanced Stage Lung Cancer, Small Cell Lung Cancer, and gene therapy for lung neoplasms.

Topics for this issue will include: Epidemiology of RCC;New Insights into the Biology of RCC;Pathology of Renal Neoplasms;Imaging in RCC;Small Renal Tumors: Prognosis and Management;The Role of Surgery in the management of RCC: Nephrectomy and metastatectomy;Cytoreductive Nephrectomy: Rationale and current Applications;Adjuvant Therapies in RCC and Management of Side Effects from Current Therapies in RCC

This book aims to provide an up-to-date review of the literature in each of the major areas relating to the management of older urological cancer patients, and makes recommendations for best practice and future research. The authors come from a broad geographic spread including the UK, mainland Europe and North America to ensure a worldwide relevance.

The difference among pluripotent stem cells, multipotent stem cells, and unipotent stem cells is pointed out. Vast therapeutic applications of the following specific stem cells in disease and tissue injury are discussed: human embryonic stem cells, human mesenchymal stem cells, germ cell-derived pluripotent stem cells, induced pluripotent stem cells, human umbilical cord blood-derived stem cells, breast tumor stem cells,and hematopoietic stem cells. Because of the potential of human embryonic stem cells to produce unlimited quantities of any human cell type, considerable focus is placed on their therapeutic potential. Because of their pluripotency, these cells have been used in various applications such as tissue engineering, regenerative medicine, pharmacological and toxicological studies, and fundamental studies of cell differentiation. The formation of embryoid bodies, which are three-dimensional aggregates of embryonic stem cells, is explained as this is the first step in cell differentiation. Such embryoid body culture has been widely used as a trigger for the in vitro differentiation of embryonic stem cells. The basic capacity of self-renewal of human embryogenic stem cells is explained. The role of TGF-beta in the propagation of human embryonic stem cells is discussed. The differentiation of human embryonic stem cells into neurons, hepatocytes, cardiomyocytes, and retinal cells is fully explained. Donor policies for hematopoietic stem cells are also explained.

Aromatase Inhibitors (AIs) treat postmenopausal estrogen receptor positive tumours, which constitute the majority of breast cancer patients. This comprehensive volume brings together the current knowledge from different relevant areas, including molecular mechanisms and translational aspects of drug resistance in AIs. Topics covered include research, experimental , and clinical data specifically focused on AI resistance in breast cancer. The volume will include three sections. The first section covers general knowledge about aromatase inhibitors, including regulation of aromatase genes, and structure and function of aromatase protein. The second section provides the detailed mechanisms of resistance to AIs, while the third section explores prediction of resistance and potential strategies to overcome resistance. Breast cancer is the most common female cancer and AIs significantly improve treatments outcomes compatibly to previously used endocrine treatments. However 10-15% of post-operative patients develop a relapse during adjuvant treatment with AIs; about 25-50% of the patients do not respond to AIs in neo-adjuvant or metastatic setting, and the majority of metastatic patients who initially respond develop resistance within 3 years. There is an important need to understand these mechanisms of resistance in order to develop methods of preventing or overcoming the resistance to AIs, which will ensure a more successful outcome in treating breast cancer.